The γ-secretase inhibitors enhance the anti-leukemic activity of ibrutinib in B-CLL cells

Ibrutinib blocks B-cell receptor signaling and interferes with leukemic cell-to-microenvironment interactions. Ibrutinib plays a key role in the management of B-CLL and is recommended for first line treatment of high-risk CLL patients with 17p deletion. Therefore, elucidating the factors governing s...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Secchiero, Paola, Voltan, Rebecca, Rimondi, Erika, Melloni, Elisabetta, Athanasakis, Emmanouil, Tisato, Veronica, Gallo, Stefania, Rigolin, Gian Matteo, Zauli, Giorgio
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2017
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5601728/
https://ncbi.nlm.nih.gov/pubmed/28938632
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.19494
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi